On 2 January, AtriCure announced the completion of the previously announced acquisition of Endoscopic Technologies (Estech), a developer of surgical ablation devices with controlled radiofrequency technology used in the treatment of atrial fibrillation.
“We are pleased to complete the acquisition of Estech, and we welcome the team to AtriCure. This transaction provides substantial benefits to AtriCure and strengthens our leadership position in the atrial fibrillation market; we are excited about the opportunities that our combined businesses will bring to our customers,” said Mike Carrel, president and chief executive officer of AtriCure.
AtriCure expects that the transaction will increase sales and marketing expense as well as research and development expenditures in order to accelerate clinical development and commercial sales of the combined product portfolio.
